Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma

Paulina Liberman, Jasmine H. Francis, Karnika Mehrotra, Jing Tian, Mark P. McGarrey, Ethan K. Sobol, Jennifer E. Thorne, Mary E. Aronow, Meghan K. Berkenstock

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate if there is a difference in the clinical course of primary vitreoretinal lymphoma (PVRL) in vitrectomized versus non-vitrectomized eyes. Methods: Observational multicenter retrospective case series of patients diagnosed with PVRL between 2007 and 2019, at three tertiary centers. The main outcomes were relapse rates, inflammatory parameters, and best-corrected visual acuities (BCVA). Statistical methods used were an adjusted generalized estimating equation model, and a proportional Cox model. Results: Eighty patients (150 eyes) were followed for a median of 1.7 years. At presentation, there were no clinical differences between the groups. The relapse rate was 0.091/eye-year (EY) for vitrectomized eyes and 0.087/EY for non-vitrectomized eyes (p = .35). Vitrectomized eyes had better BCVA than non-vitrectomized eyes (p < .001). Conclusions: Vitrectomy had no effect on the relapse rate in eyes with PVRL. However, the decrease in vitreous cell and debris led to vitrectomized eyes having better visual acuity than non-vitrectomized eyes.

Original languageEnglish (US)
Pages (from-to)496-500
Number of pages5
JournalOcular Immunology and Inflammation
Volume31
Issue number3
DOIs
StatePublished - 2023

Keywords

  • Primary vitreoretinal lymphoma
  • ocular lymphoma
  • vitrectomy

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma'. Together they form a unique fingerprint.

Cite this